{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:38:48Z","timestamp":1790123928370,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":338,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Severe alcohol-associated hepatitis (SAH) patients with infections have a high short-term mortality rate. Gut microbiota dysbiosis plays an important role in the pathogenesis of SAH. Preliminary studies have demonstrated long-term benefits with healthy donor fecal microbiota transplantation (FMT). Data on FMT compared with pentoxifylline for SAH and relevant gut microbial changes are lacking in literature.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From January 2019 to February 2021, retrospective analysis of a single hospital\u2019s records revealed 47 SAH patients undergoing FMT (100\u2009mL\/day via nasoduodenal tube for 7\u2009days) and 25 matched patients receiving pentoxifylline (400\u2009mg\/8 h for 28\u2009days). The primary end point was a 6-month survival rate. Secondary end points included incidence of ascites, hepatic encephalopathy, infections, acute kidney injury, and gut microbiota changes between post-therapy groups. Biomarker discovery and network analysis were also performed to identify significant taxa of gut microbiota in post-treatment groups in retrospectively stored stool samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All were males. The 6-month survival rate was higher in the patients undergoing FMT than in patients receiving pentoxifylline (83.0% vs 56.0%, P\u2009=\u20090.012). At the end of 6-month follow-up, the incidences of clinically significant ascites (56.0% vs 25.5%, P\u2009=\u20090.011), hepatic encephalopathy (40.0% vs 10.6%, P\u2009=\u20090.003), and critical infections (52.0% vs 14.9%, P\u2009&amp;lt;\u20090.001) in patients administered pentoxifylline were significantly higher than those in patients treated with FMT. At 3\u2009months, biomarker analysis revealed a significant abundance of Bifidobacterium and Eggerthella in the FMT group and the pentoxifylline group, respectively. At 6\u2009months, Bifidobacterium in the FMT group and pathogenic Aerococcaceae in the pentoxifylline group were notable. Network analysis showed beneficial taxa (Bifidobacterium) as a central influencer in those undergoing FMT at 6\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Healthy donor FMT improved survival rate and reduced liver-related complications compared with pentoxifylline. These clinical benefits were associated with favorable modulation of intestinal bacterial communities. Difficult-to-treat SAH patients may be safely bridged to transplantation using FMT. Controlled trials evaluating long-term outcomes are an unmet need.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/gastro\/goac074","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:45:32Z","timestamp":1670273132000},"source":"Crossref","is-referenced-by-count":30,"title":["Clinical outcomes and gut microbiota analysis of severe alcohol-associated hepatitis patients undergoing healthy donor fecal transplant or pentoxifylline therapy: single-center experience from Kerala"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-336X","authenticated-orcid":false,"given":"Cyriac Abby","family":"Philips","sequence":"first","affiliation":[{"name":"Clinical and Translational Hepatology, The Liver Institute, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"},{"name":"Monarch Liver Laboratory, The Liver Institute, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ahamed","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Advanced GI Endoscopy, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasidharan","family":"Rajesh","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobhit","family":"Singh","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Radiology, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit","family":"Tharakan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Advanced GI Endoscopy, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsha K","family":"Abduljaleel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Advanced GI Endoscopy, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Augustine","sequence":"additional","affiliation":[{"name":"Monarch Liver Laboratory, The Liver Institute, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"},{"name":"Department of Gastroenterology and Advanced GI Endoscopy, Center of Excellence in GI Sciences, Rajagiri Hospital , Chunangamvely, Aluva, Ernakulam, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"2022120520450861800_goac074-B1","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3748\/wjg.v20.i9.2159","article-title":"Pharmacotherapy of acute alcoholic hepatitis in clinical practice","volume":"20","author":"Abenavoli","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2022120520450861800_goac074-B2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.gastrohep.2014.02.001","article-title":"Alcoholic hepatitis: prognosis and treatment","volume":"37","author":"Casanova","year":"2014","journal-title":"Gastroenterol Hepatol"},{"key":"2022120520450861800_goac074-B3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1745-6215-14-262","article-title":"Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial","volume":"14","author":"Forrest","year":"2013","journal-title":"Trials"},{"key":"2022120520450861800_goac074-B4","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s10620-014-3173-8","article-title":"Alcoholic hepatitis: current management","volume":"59","author":"Spengler","year":"2014","journal-title":"Dig Dis Sci"},{"key":"2022120520450861800_goac074-B5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","article-title":"A histologic scoring system for prognosis of patients with alcoholic hepatitis","volume":"146","author":"Altamirano","year":"2014","journal-title":"Gastroenterology"},{"key":"2022120520450861800_goac074-B6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/17474124.2014.903800","article-title":"Prognosis and treatment of patients with acute alcoholic hepatitis","volume":"8","author":"Papastergiou","year":"2014","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2022120520450861800_goac074-B7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MCG.0000000000000674","article-title":"Treatment of severe alcoholic hepatitis with corticosteroid, pentoxifylline, or dual therapy: a systematic review and meta-analysis","volume":"51","author":"Lee","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"2022120520450861800_goac074-B8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4254\/wjh.v3.i8.215","article-title":"Liver transplantation in acute alcoholic hepatitis: current status and future development","volume":"3","author":"Singal","year":"2011","journal-title":"World J Hepatol"},{"key":"2022120520450861800_goac074-B9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"2022120520450861800_goac074-B10","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.12279","article-title":"Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis","volume":"37","author":"Parker","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2022120520450861800_goac074-B11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022120520450861800_goac074-B12","first-page":"87","article-title":"Modulating the intestinal microbiota: therapeutic opportunities in liver disease","volume":"8","author":"Philips","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"2022120520450861800_goac074-B13","first-page":"854","article-title":"Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis","volume":"44","author":"Eiseman","year":"1958","journal-title":"Surgery"},{"key":"2022120520450861800_goac074-B14","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2015-310585","article-title":"Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease","volume":"65","author":"Llopis","year":"2016","journal-title":"Gut"},{"key":"2022120520450861800_goac074-B15","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jhep.2016.11.008","article-title":"Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice","volume":"66","author":"Ferrere","year":"2017","journal-title":"J Hepatol"},{"key":"2022120520450861800_goac074-B16","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"2022120520450861800_goac074-B17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12664-018-0859-4","article-title":"Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis","volume":"37","author":"Philips","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"2022120520450861800_goac074-B18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2018.10.004","article-title":"Only in the darkness can you see the stars: severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure","volume":"70","author":"Philips","year":"2019","journal-title":"J Hepatol"},{"key":"2022120520450861800_goac074-B19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s12072-022-10312-z","article-title":"Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial","volume":"16","author":"Sharma","year":"2022","journal-title":"Hepatol Int"},{"key":"2022120520450861800_goac074-B20","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/hep.29306","article-title":"Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial","volume":"66","author":"Bajaj","year":"2017","journal-title":"Hepatology"},{"key":"2022120520450861800_goac074-B21","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/hep.30037","article-title":"Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant","volume":"68","author":"Bajaj","year":"2018","journal-title":"Hepatology"},{"key":"2022120520450861800_goac074-B22","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis: analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"Philips","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2022120520450861800_goac074-B23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.jhep.2011.05.015","article-title":"Pathways of liver injury in alcoholic liver disease","volume":"55","author":"Tilg","year":"2011","journal-title":"J Hepatol"},{"key":"2022120520450861800_goac074-B24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.3389\/fmicb.2019.01398","article-title":"Multiple-omics techniques reveal the role of glycerophospholipid metabolic pathway in the response of Saccharomyces cerevisiae against hypoxic stress","volume":"10","author":"Xia","year":"2019","journal-title":"Front Microbiol"},{"key":"2022120520450861800_goac074-B25","doi-asserted-by":"crossref","first-page":"493564","DOI":"10.1155\/2013\/493564","article-title":"Propionibacterium acnes in human health and disease","volume":"2013","author":"McDowell","year":"2013","journal-title":"Biomed Res Int"},{"key":"2022120520450861800_goac074-B26","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.BAD-0010-2016","article-title":"Bifidobacteria and their health-promoting effects","volume":"5","author":"Hidalgo-Cantabrana","year":"2017","journal-title":"Microbiol Spectr"},{"key":"2022120520450861800_goac074-B27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3389\/fmicb.2016.00925","article-title":"Bifidobacteria and their role as members of the human gut microbiota","volume":"7","author":"O'Callaghan","year":"2016","journal-title":"Front Microbiol"},{"key":"2022120520450861800_goac074-B28","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1038\/s41467-020-18871-1","article-title":"Health and disease markers correlate with gut microbiome composition across thousands of people","volume":"11","author":"Manor","year":"2020","journal-title":"Nat Commun"},{"key":"2022120520450861800_goac074-B29","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1128\/IAI.00493-09","article-title":"Community-wide response of the gut microbiota to enteropathogenic Citrobacter rodentium infection revealed by deep sequencing","volume":"77","author":"Hoffmann","year":"2009","journal-title":"Infect Immun"},{"key":"2022120520450861800_goac074-B30","doi-asserted-by":"crossref","first-page":"e00303-20","DOI":"10.1128\/mSystems.00303-20","article-title":"Citrobacter species increase energy harvest by modulating intestinal microbiota in fish: nondominant species play important functions","volume":"5","author":"Zhang","year":"2020","journal-title":"mSystems"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goac074\/47605420\/goac074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goac074\/47605420\/goac074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T20:45:43Z","timestamp":1670273143000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goac074\/6873940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goac074","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"goac074"}}